S&P 500   3,113.57 (-0.21%)
DOW   27,848.04 (-0.31%)
QQQ   202.92 (-0.22%)
CGC   17.75 (+15.86%)
BABA   183.19 (-1.11%)
T   36.59 (-3.71%)
ACB   2.67 (+14.13%)
F   8.78 (-1.35%)
PRI   132.65 (+0.77%)
DIS   147.50 (-0.59%)
S&P 500   3,113.57 (-0.21%)
DOW   27,848.04 (-0.31%)
QQQ   202.92 (-0.22%)
CGC   17.75 (+15.86%)
BABA   183.19 (-1.11%)
T   36.59 (-3.71%)
ACB   2.67 (+14.13%)
F   8.78 (-1.35%)
PRI   132.65 (+0.77%)
DIS   147.50 (-0.59%)
S&P 500   3,113.57 (-0.21%)
DOW   27,848.04 (-0.31%)
QQQ   202.92 (-0.22%)
CGC   17.75 (+15.86%)
BABA   183.19 (-1.11%)
T   36.59 (-3.71%)
ACB   2.67 (+14.13%)
F   8.78 (-1.35%)
PRI   132.65 (+0.77%)
DIS   147.50 (-0.59%)
S&P 500   3,113.57 (-0.21%)
DOW   27,848.04 (-0.31%)
QQQ   202.92 (-0.22%)
CGC   17.75 (+15.86%)
BABA   183.19 (-1.11%)
T   36.59 (-3.71%)
ACB   2.67 (+14.13%)
F   8.78 (-1.35%)
PRI   132.65 (+0.77%)
DIS   147.50 (-0.59%)
Log in

Biohaven Pharmaceutical Stock Price, Forecast & Analysis (NYSE:BHVN)

$53.00
+1.44 (+2.79 %)
(As of 11/20/2019 12:52 PM ET)
Today's Range
$51.29
Now: $53.00
$53.12
50-Day Range
$40.99
MA: $45.76
$51.78
52-Week Range
$29.17
Now: $53.00
$67.86
Volume14,619 shs
Average Volume496,758 shs
Market Capitalization$2.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.34
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:BHVN
CUSIPN/A
Phone203-404-0410

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.74 per share

Profitability

Net Income$-240,920,000.00

Miscellaneous

Employees63
Market Cap$2.77 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.


Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) released its quarterly earnings results on Friday, November, 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.57) by $0.47. View Biohaven Pharmaceutical's Earnings History.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Biohaven Pharmaceutical.

What price target have analysts set for BHVN?

10 brokerages have issued 1 year price objectives for Biohaven Pharmaceutical's shares. Their forecasts range from $50.00 to $100.00. On average, they anticipate Biohaven Pharmaceutical's share price to reach $74.44 in the next twelve months. This suggests a possible upside of 41.0% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.

What is the consensus analysts' recommendation for Biohaven Pharmaceutical?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.

What are Wall Street analysts saying about Biohaven Pharmaceutical stock?

Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (10/21/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We are reiterating our Overweight rating and raising our PT on BHVN to $75 from $65. The price target upgrade is a result of recent, but ongoing, due diligence in the space that refines our thinking on the evolving treatment paradigm. As a result, we have recast our model, now based on assumed use in certain target populations that we believe would be most appropriate for oral CGRPs. Namely, this includes the migraine patients contraindicated for triptans and those patients that fail to consistently respond to/tolerate triptans." (2/8/2019)

Has Biohaven Pharmaceutical been receiving favorable news coverage?

News stories about BHVN stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a news impact score of -5.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Biohaven Pharmaceutical.

Are investors shorting Biohaven Pharmaceutical?

Biohaven Pharmaceutical saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 7,020,000 shares, an increase of 6.2% from the September 15th total of 6,610,000 shares. Based on an average daily trading volume, of 673,100 shares, the short-interest ratio is presently 10.4 days. Approximately 16.3% of the shares of the company are sold short. View Biohaven Pharmaceutical's Current Options Chain.

Who are some of Biohaven Pharmaceutical's key competitors?

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), Biopharmx (BPMX), Alibaba Group (BABA), Aurinia Pharmaceuticals (AUPH), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Baidu (BIDU), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD) and Global Blood Therapeutics (GBT).

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the folowing people:
  • Dr. Vladimir Coric, CEO & Director (Age 48)
  • Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 55)
  • Dr. Charles Conway, Chief Scientific Officer (Age 57)
  • Mr. Clifford Bechtold, Chief Operating Officer
  • Mr. Matthew DeLawder, Director of Accounting

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (1.89%), Emerald Advisers LLC (0.61%), Emerald Mutual Fund Advisers Trust (0.58%), Handelsbanken Fonder AB (0.44%), GW&K Investment Management LLC (0.28%) and California Public Employees Retirement System (0.12%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.

Which major investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Emerald Advisers LLC, Essex Investment Management Co. LLC, Emerald Mutual Fund Advisers Trust and Sigma Planning Corp. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Eric Aguiar, John Tilton, Julia P Gregory and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

Which major investors are buying Biohaven Pharmaceutical stock?

BHVN stock was bought by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, GW&K Investment Management LLC, California Public Employees Retirement System, Columbus Circle Investors, Handelsinvest Investeringsforvaltning, Russell Investments Group Ltd., NJ State Employees Deferred Compensation Plan and WCM Investment Management LLC. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $52.80.

How big of a company is Biohaven Pharmaceutical?

Biohaven Pharmaceutical has a market capitalization of $2.76 billion. The company earns $-240,920,000.00 in net income (profit) each year or ($6.15) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.View Additional Information About Biohaven Pharmaceutical.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.


MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  313 (Vote Underperform)
Total Votes:  585
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel